Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 856 to 870 of 1553 results for do not do recommendations

  1. People with limited mobility:- How effective and cost effective are environmental changes to increase physical activity among people with limited mobility because of either enduring or life-stage specific factors (for example, small children, parents with prams or buggies, disabled people including those with sensoryimpairments and learning disabilities, older people, people with dementia and their carers)? Are effects maintained over time?

    Recommendation ID NG90/4 Question People with limited mobility:- How effective and cost effective are environmental changes to increase

    Research recommendation
    Published
    15 November 2018

  2. Reducing car ownership:- Does reducing car use or ownership change physical activity levels? Are effects maintained over time?

    Recommendation ID NG90/5 Question Reducing car ownership:- Does reducing car use or ownership change physical activity levels? Are...

    Research recommendation
    Published
    15 November 2018

  3. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

    Medtech innovation briefing
    Published
    29 November 2016

  4. Liposuction for chronic lipoedema (IPG721)

    Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat.

    Interventional procedures guidance
    Published
    29 March 2022
    View recommendations

    Sections for IPG721

  5. NICE HealthTech programme manual (PMG48)

    This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme

  6. The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns. However, current evidence on its efficacy is limited in quality and quantity. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG656/1 Question The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder

    Research recommendation
    Published
    15 November 2019

  7. Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the incidence of dementia?

    Recommendation ID NG98/3 Question Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing

    Research recommendation
    Published
    10 December 2018

  8. Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

    Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.

    Technology appraisal guidance
    Published
    27 March 2024
    View recommendations

    Sections for TA958

  9. Extended access to GP services:- Is extended access to GP services, for example during early mornings, evenings and weekends, more clinically and cost effective than standard access?

    Recommendation ID NG94/1 Question Extended access to GP services:- Is extended access to GP services, for example during early mornings

    Research recommendation
    Published
    15 November 2018

  10. Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

    Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Last updated
    1 August 2013
    View recommendations

    Sections for TA215

  11. Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

    Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.

    Technology appraisal guidance
    Published
    24 April 2013
    View recommendations

    Sections for TA279

  12. What is the most clinically and cost-effective treatment for diverticular disease?

    Recommendation ID NG147/3 Question What is the most clinically and cost-effective treatment for diverticular disease? Any explanatory

    Research recommendation
    Published
    10 February 2020

  13. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    Recommendation ID NG52/2 Question Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In...

    Research recommendation
    Published
    25 August 2016

  14. Management of stable angina in people with evidence of ischaemia on non-invasive functional testing:- Do people with stable angina and evidence of reversible ischaemia on noninvasive functional testing who are on optimal drug treatment benefit from routine coronary angiography with a view to revascularisation?

    Recommendation ID CG126/2 Question Management of stable angina in people with evidence of ischaemia on non-invasive functional testing:-

    Research recommendation
    Published
    9 June 2015

  15. Tocilizumab for the treatment of rheumatoid arthritis (TA247)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    22 February 2012
    View recommendations

    Sections for TA247